title: Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder.
abstract: OBJECTIVE
  We evaluated the efficacy and tolerability of the nicotinic channel modulator dexmecamylamine for overactive bladder.
  
  
  METHODS
  This was a randomized, double-blind, placebo controlled trial in 768 randomized subjects. Those with at least a 6-month history of overactive bladder were randomized to 0.5, 1 or 2 mg dexmecamylamine or placebo in a ratio of 1:1:1:2, respectively. Subjects completed a 3-day diary before each visit associated with the 12-week treatment period. They were required to have 8 or more micturitions per day and 3 or more urinary urge incontinent episodes per day if overactive bladder wet at the end of a placebo run-in period. Co-primary end points for the study included a change from baseline 1) in micturition frequency per 24 hours at week 12 and 2) in urge urinary incontinence episodes per 24 hours at week 12. Secondary end points were voided volume, nocturia episodes, OABq (Overactive Bladder Questionnaire) and urgency questionnaire.
  
  
  RESULTS
  Dexmecamylamine (2 mg) produced a statistically significant decrease in micturition frequency (p = 0.03) but did not produce a statistically significant decrease in urge incontinence (wet) episodes (p = 0.38). Secondary end points, including volume voided in the 1 mg group only, CGI-I (Clinical Global Impression of Improvement), visual analog scale urgency impact, intensity and severity, were statistically significant at week 12 for the 2 mg dose. Dexmecamylamine was well tolerated in this subject population with a low incidence of discontinuations due to adverse effects. Constipation, dry mouth and urinary tract infection showed a dose dependent increase in frequency.
  
  
  CONCLUSIONS
  Dexmecamylamine does not appear to offer an enhanced therapeutic profile for the treatment of overactive bladder relative to current therapies.
authors.affiliation: Oakland University William Beaumont School of Medicine, Royal Oak, Michigan.
authors.forename: Michael
authors.initials: M
authors.lastname: Chancellor
authors.affiliation: Robert Wood Johnson Medical School, New Brunswick, New Jersey.
authors.forename: Eboo
authors.initials: E
authors.lastname: Versi
authors.affiliation: Targacept, Inc., Winston-Salem, North Carolina.
authors.forename: Chris
authors.initials: C
authors.lastname: Dvergsten
authors.affiliation: Targacept, Inc., Winston-Salem, North Carolina.
authors.forename: Steven
authors.initials: S
authors.lastname: Toler
mesh_terms: D000368:Aged; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011978:Receptors, Nicotinic / Q000187:drug effects*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D014554:Urination / Q000187:drug effects*
chemical_list: D018727:Muscarinic Antagonists; D011978:Receptors, Nicotinic; C403530:nicotinic receptor alpha3beta4
keywords: drug tolerance; nicotinic; overactive; receptors; treatment outcome; urge; urinary bladder; urinary incontinence